Article Synopsis
- Atrial fibrillation (AF) is commonly overlooked by noncardiologists, which this study addressed by evaluating the impact of artificial intelligence-enabled ECG (AI-ECG) alerts on AF diagnosis and prescriptions.
- In a randomized controlled trial with noncardiologists at two hospitals in Taiwan, those receiving AI-ECG alerts showed significantly higher rates of non-vitamin K antagonist oral anticoagulant prescriptions and new AF diagnoses compared to the control group.
- The study concluded that AI-ECG alerts can improve AF management by noncardiologists, potentially enhancing overall care quality for patients at risk of AF.
Video Abstracts
Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Atrial fibrillation (AF) is often underdiagnosed and undertreated by noncardiologists. This study evaluated whether artificial intelligence-enabled ECG (AI-ECG) alerts could improve AF diagnosis and non-vitamin K antagonist oral anticoagulant prescriptions by noncardiologists.
Methods: In this open-label, cluster randomized controlled trial (NCT05127460) at 2 hospitals in Taiwan, noncardiologists were randomized to an intervention group (AI-ECG alerts) or control group (usual care). Alerts were sent to physicians when AI-ECG identified AF in emergency or hospitalized patients at risk of stroke (CHA₂DS₂-VASc ≥1 for men, ≥2 for women), excluding those with prior AF or oral anticoagulant use. Primary end points included a non-vitamin K antagonist oral anticoagulant prescription within 90 days after discharge, new AF diagnosis, echocardiogram arrangements, and cardiologist visits. Secondary end points were ischemic stroke, cardiovascular death, and all-cause death.
Results: A total of 8857 and 8960 patients were treated by 120 and 113 noncardiologists in the intervention and control groups, respectively; 275 and 245 patients had AI-detected AF. The non-vitamin K antagonist oral anticoagulant prescription rate was significantly higher in the intervention group (23.3% versus 12.0%; hazard ratio [HR], 1.85 [95% CI, 1.11-3.07]). The intervention group also had a higher rate of AF diagnosis (HR, 1.40 [95% CI, 1.03-1.90]). No significant differences were observed in echocardiogram arrangements, cardiologist visits, or the rates of ischemic stroke, cardiovascular death, and all-cause death.
Conclusions: An AI-ECG alert for AF identification promoted non-vitamin K antagonist oral anticoagulant prescriptions among noncardiologists, thus reducing the disparity in AF care quality between cardiologists and noncardiologists.
Registration: URL: https://clinicaltrials.gov/; Unique identifier: NCT05127460.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/JAHA.125.042106 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral anticoagulant therapy for patients with atrial fibrillation on long-term dialysis: A network meta-analysis of 137,574 patients.
Eur J Clin Invest
September 2025
Liverpool Centre for Cardiovascular Science, at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
Background: Patients with atrial fibrillation (AF) with end-stage renal failure on renal replacement therapy are at high risk of stroke and bleeding, but the optimal oral anticoagulation (OAC) strategy is uncertain. To investigate the most effective OAC therapy for patients with AF on long-term dialysis.
Methods: PubMed, EMBASE and Web of Science databases were systematically searched from inception to 9 October 2024 to identify relevant studies on OAC strategy for patients with AF on long-term dialysis.
Clinical characteristics, therapeutic strategies, and outcomes in elderly patients on oral anticoagulant therapy undergoing percutaneous coronary interventions: analysis of the PERSEO Registry.
J Geriatr Cardiol
August 2025
Interventional Cardiology, Sandro Pertini Hospital, Rome, Italy.
Background: Antithrombotic strategies after percutaneous coronary interventions (PCI) in elderly patients on oral anticoagulant therapy (OAT) are debated due to the balance between ischemic and bleeding risks. Recent guidelines recommend early transitioning from triple antithrombotic therapy to dual antithrombotic therapy, but there are limited data on elderly patients.
Methods: We performed a age-specific analysis of the PERSEO Registry population aimed to compare clinical features, therapeutic strategies, and outcomes of individuals aged ≥ 80 years and < 80 years who were on OAT and underwent PCI with stent.
Rivaroxaban alleviates hepatic sinusoidal obstruction syndrome in mice by modulating the gut microbiota and inhibiting the PI3K/Akt signaling pathway.
Front Microbiol
August 2025
Department of Allergy, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Introduction: Hepatic sinusoidal obstruction syndrome (HSOS) is a vascular liver disease with a high mortality rate, and treatment methods are limited. Rivaroxaban is an oral anticoagulant. This study aimed to investigate the pharmacological effect and potential mechanism of rivaroxaban on HSOS.
View Article and Find Full Text PDFReduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials.
Res Pract Thromb Haemost
July 2025
Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles, California, USA.
Background: Venous thromboembolism (VTE) is a major cause of cardiovascular morbidity and mortality globally. Although direct oral anticoagulants (DOACs) have improved extended VTE treatment, the optimal dose for balancing efficacy and safety remains unclear.
Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of reduced-dose DOACs vs full-dose regimens during extended anticoagulation for VTE.
High- and intermediate-risk pulmonary embolism in pediatric tertiary care centers in the Netherlands.
Res Pract Thromb Haemost
August 2025
Department of Pediatric Hematology, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, the Netherlands.
Background: Pulmonary embolism (PE) response teams are increasingly used in adult care to improve severe PE management. Understanding the epidemiology, treatment, and outcomes of severe PE in children is crucial to assessing the need for pediatric PE response teams in the Netherlands.
Objectives: To evaluate the incidence, management, and short-term outcomes of severe PE in Dutch pediatric patients.